MENU
+Compare
BLTE
Stock ticker: NASDAQ
AS OF
Jul 30, 04:59 PM (EDT)
Price
$65.20
Change
+$1.61 (+2.53%)
Capitalization
2.11B

BLTE Belite Bio Forecast, Technical & Fundamental Analysis

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout... Show more

BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BLTE with price predictions
Jul 29, 2025

BLTE in upward trend: price rose above 50-day moving average on July 25, 2025

BLTE moved above its 50-day moving average on July 25, 2025 date and that indicates a change from a downward trend to an upward trend. In of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 28 cases where BLTE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 29, 2025. You may want to consider a long position or call options on BLTE as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BLTE just turned positive on July 08, 2025. Looking at past instances where BLTE's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLTE advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day moving average for BLTE crossed bearishly below the 50-day moving average on July 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for BLTE moved below the 200-day moving average on July 11, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLTE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BLTE broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BLTE entered a downward trend on July 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLTE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.351) is normal, around the industry mean (18.138). P/E Ratio (0.000) is within average values for comparable stocks, (60.154). BLTE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.604). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (278.954).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLTE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BLTE is expected to report earnings to rise 43.70% to -38 cents per share on August 06

Belite Bio BLTE Stock Earnings Reports
Q2'25
Est.
$-0.39
Q1'25
Beat
by $0.10
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.05
The last earnings report on May 14 showed earnings per share of -27 cents, beating the estimate of -37 cents. With 30.55K shares outstanding, the current market capitalization sits at 2.11B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
12750 High Bluff Drive
Phone
+1 858 246-6240
Employees
20
Web
https://www.belitebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAIIX18.32N/A
N/A
iShares MSCI EAFE Intl Idx Instl
IVFCX4.21N/A
N/A
Federated Hermes Intl Strat Val Div C
MBCGX21.25N/A
N/A
MassMutual Blue Chip Growth A
MMYAX8.56N/A
N/A
MassMutual Small Company Value A
NRILX15.50N/A
N/A
Neuberger Berman International Sel R6

BLTE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BLTE has been loosely correlated with RAIN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BLTE jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
+2.26%
RAIN - BLTE
48%
Loosely correlated
+1.07%
ACOG - BLTE
24%
Poorly correlated
-4.83%
LENZ - BLTE
23%
Poorly correlated
+0.60%
NAMS - BLTE
23%
Poorly correlated
-2.99%
AGIO - BLTE
23%
Poorly correlated
+1.51%
More